# Amneal Pharmaceuticals (AMRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AMRX
## Company Profile
- Ticker: AMRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Generics
## Stock Data
- Close: 21.7 USD
- Market cap: 4035638318.8 USD
- Last updated: 2026-11-12
## Business Overview
### Diversified Pharmaceutical Company
Amneal Pharmaceuticals expands access to affordable and branded medicines through a portfolio of approximately 300 products. The company delivers retail generics, injectables, biosimilars and specialty medicines, primarily in the United States.
### Affordable Medicines
The Affordable Medicines segment includes complex generics, injectable products and biosimilars. Its scale and manufacturing network support a broad prescription base and recurring product launches across multiple dosage forms.
### Specialty Portfolio
Amneal's branded Specialty business focuses on neurology and endocrinology. Key therapeutic areas include Parkinson's disease, migraine and thyroid disease, supported by products such as CREXONT, BREKIYA and UNITHROID.
### Distribution Operations
The AvKARE segment distributes pharmaceuticals and medical products to federal, retail and institutional customers in the United States. This business adds a distinct channel alongside Amneal's manufacturing and branded-commercial operations.
## Why The Stock Is Moving

As of Nov 12, 2026, AMRX was little changed and closed at $21.70. No new same-company headline was identified in the current news window.

## Recent News
- 2026-11-10 21:02 EST — [Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers](https://biopharmsignal.com/news/AMRX/amneal-named-biospace-2027-best-place-to-work-ranking-no-1-among-large-employers-1cb40ef3) — Source: Amneal Pharmaceuticals
- 2026-11-03 11:00 EST — [Amneal Reports Third Quarter 2026 Financial Results](https://biopharmsignal.com/news/AMRX/amneal-reports-third-quarter-2026-financial-results-5dc23eaf) — Source: Amneal Pharmaceuticals
- 2026-10-08 12:00 EST — [Amneal to Report Third Quarter 2026 Results on November 3, 2026](https://biopharmsignal.com/news/AMRX/amneal-to-report-third-quarter-2026-results-on-november-3-2026-b9da76cc) — Source: Amneal Pharmaceuticals
- 2026-09-18 20:01 EST — [Amneal Announces FDA Approval and Launch of Lanreotide Injection](https://biopharmsignal.com/news/AMRX/amneal-announces-fda-approval-and-launch-of-lanreotide-injection-600bd4a1) — Source: Amneal Pharmaceuticals
- 2026-08-10 12:00 EST — [Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader](https://biopharmsignal.com/news/AMRX/amneal-completes-acquisition-of-kashiv-biosciences-creating-a-global-biosimilar--72e33362) — Source: Amneal Pharmaceuticals
